|Medical Services||Locations||Patient/Visitor Info||Programs & Support||Points of Pride|
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
Last Modified: 6/5/2012 First Published: 6/5/2008
Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether sunitinib is more effective than aplacebo in treatingnon-small cell lung cancer.
This randomized phase III trial is studying sunitinib to see how well it works when given as maintenance therapycompared with a placebo in treating patients withstage III or stage IV non-small cell lung cancer previously treated with combination chemotherapy.
Eligibility criteriainclude the following:
Final eligibility for a clinical trial is determined by the health professionals conducting the trial.
Patients will be randomly assigned (have an equal chance of being placed) to one of two treatment groups.
Patients in group one will receive sunitinib by mouth once a day for as long as benefit is shown.
Patients in group two will receive a placebo by mouth once a day for as long as benefit is shown.
After finishing treatment, patients will be evaluated every 3 months for 1 year, every 6 months for 1 year and then periodically for 3 years.
Trial Contact Information
Blanche Reiner RN OCN 610-738-2515
Nona Blauvelt MSN AOCN 610-738-2522
Last Updated: 1/6/2014